“Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD”. SKIN The Journal of Cutaneous Medicine 10, no. 2 (March 10, 2026): s731. Accessed April 30, 2026. https://skin.dermsquared.com/skin/article/view/4038.